

What is your professional role?

SITC Workshop on New Perspectives for Target Antigens in the Changing Cancer Immunotherapy Landscape Thursday, November 5, 2015

This form is for your evaluation of this educational activity. Please provide your input on the format, goals and other items that affect your meeting experience.

Please fill out circles carefully and completely, like this:

By providing your name and contact information, you will be entered into a drawing for a chance to win one of three \$100 Amazon gift cards. **Note: To receive CME credits, you** *must* fill out the evaluation along with your contact information.

Clinical Come Clinical /Dunaticina							
Oncologist	\circ	Clinical Care: Physician Assistant	\bigcirc	Scientific Research: Basic			
Clinical Care: Nurse	\bigcirc	Clinical Care: Social Worker	\bigcirc	Scientific Research: Clinical			
Clinical Care: Nurse Practitioner	\bigcirc	Clinical Care: Other	\bigcirc	Scientific Research: Translational			
Clinical Care: Patient Advocate	\bigcirc	Industry	\bigcirc	Other			
Clinical Care: Pharmacist	\bigcirc	Scientist-in-Training/Student					
ich of the following best describes	your <i>p</i>	primary work setting?					
Academic Medical Center	\bigcirc	Community Hospital without Training Program	\bigcirc	Government/Regulatory			
Clinic Group Independent	\circ	Industry/Biotech (1-50 Employees)	\circ	Solo Private Practice			
Clinic Group Owned	\bigcirc	Industry/Biotech (51-500 Employees)	\bigcirc	Other			
Community Hospital with Training Program	0	Industry/Biotech (500+ Employees)					
hat is your area of specialization?							
Biochemistry	\bigcirc	Internal Medicine		Oncology, Radiation / Radiation Biology			
Cellular Biology	\bigcirc	Microbiology		Oncology, Surgical			
Clinical Investigations/Clinical Trials	\circ	Molecular Biology		Pathology			
Dermatology	\circ	Oncology, Hematology		O Pharmacology/Toxicology			
Genetics and Genomics	\bigcirc	Oncology, Medical		 Stem Cell Biology 			
Immunology	\bigcirc	Oncology, Other		 Transplantation 			
Immunotherapy	\bigcirc	Oncology, Pediatric		Other			
	Clinical Care: Nurse Clinical Care: Nurse Practitioner Clinical Care: Patient Advocate Clinical Care: Pharmacist ich of the following best describes Academic Medical Center Clinic Group Independent Clinic Group Owned Community Hospital with Training Program hat is your area of specialization? Biochemistry Cellular Biology Clinical Investigations/Clinical Trials Dermatology Genetics and Genomics Immunology	Oncologist Clinical Care: Nurse Clinical Care: Nurse Practitioner Clinical Care: Patient Advocate Clinical Care: Pharmacist ich of the following best describes your particular Academic Medical Center Clinic Group Independent Clinic Group Owned Community Hospital with Training Program hat is your area of specialization? Biochemistry Cellular Biology Clinical Investigations/Clinical Trials Dermatology Genetics and Genomics Immunology	Oncologist Clinical Care: Nurse Clinical Care: Nurse Clinical Care: Nurse Practitioner Clinical Care: Patient Advocate Clinical Care: Patient Advocate Clinical Care: Pharmacist Scientist-in-Training/Student Scientist-in-Training/Student Scientist-in-Training/Student Community Hospital without Training Program Industry/Biotech (1-50 Employees) Industry/Biotech (51-500 Employees) Industry/Biotech (51-500 Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Internal Medicine Cellular Biology Clinical Investigations/Clinical Trials Dermatology Genetics and Genomics Oncology, Hematology Genetics and Genomics Oncology, Other	Oncologist Clinical Care: Nurse Clinical Care: Nurse Practitioner Clinical Care: Patient Advocate Clinical Care: Pharmacist Community Hospital without Training Program Community Hospital without Training Program Industry/Biotech (1-50 Employees) Industry/Biotech (51-500 Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Industry/Biotech (500+ Employees) Cellular Biology Clinical Investigations/Clinical Trials Dermatology Cncology, Hematology Genetics and Genomics Oncology, Medical Immunology Oncology, Other			



How long have you bee	n practicing medicine (if app	olicable)?							
O More than 20 years	○ 6 – 10 years	O Less than 1 year							
○ 11 – 20 years	○ 1 – 5 years		O I do not directly provide care						
How many patients with	n cancer do you currently see	e each weel	(if app	licable)?					
O Fewer than 5	O 16 – 25	O 30	6 – 45		O 56	or more			
O 6 – 15	O 26 – 35	O 40	6 – 55		le				
	tional activity, I am better a	Yes	No	Some what	Not Applicable				
	thes to the identification of turn roteomic and bioinformatics m	\circ	\bigcirc	\circ	\circ				
	ating T cells, T cell receptors a doptive immunotherapies.	nd chimeric	antigen	0	0	0	0		
Identify the opportunities of effective cancer va	and challenges associated wince	0	0	0	0				
Describe the results of stucheckpoint blockade.	udies aimed at identifying anti	gens targete	ed by	0	\circ	\circ	\circ		
How would you rate the	e following measures?	Strongly Agree	Agree	Unsure	Disagree	Strongly Disagree	Not Applicable		
This activity met the prog educational needs.	ram goals and my	\circ	\circ	\circ	\circ	\circ	0		
The Workshop maintained presentations that dissimmunotherapeutic a assessment of the risl presented in a balance	scussed specific gents, fair and accurate cs and benefits were	0	0	0	0	0	0		
The Workshop was free fr	rom commercial bias.	0	\circ	\circ	\circ	0	0		
The Workshop faculty we materials	re effective in presenting the	\circ	\circ	\circ	\circ	\circ	\circ		





Presenter Ratings	Excellent	Very Good	Good	Fair	Poor						
Session I: Approaches used to Identify Tumor Ar		0000	3 000								
Elaine Mardis, PhD	\circ	\bigcirc	\bigcirc	\bigcirc	\circ						
Victor H. Engelhard, PhD	\circ	\circ	\circ	\bigcirc	\circ						
Sergio A. Quezada, PhD	\circ	\bigcirc	\bigcirc	\bigcirc	\circ						
Session II: Characterization and Isolation of Spec											
John Haanen, PhD	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc						
Eric Tran, PhD	\circ	\bigcirc	\bigcirc	\bigcirc	\bigcirc						
Laurence J.N. Cooper, MD, PhD	\circ	\bigcirc	\circ	\bigcirc	\circ						
Session III: Antigen Discovery: Enabling the Next Generation of Immunotherapies											
Ugur Sahin, MD	\circ	\bigcirc	\bigcirc	\circ	\circ						
Alexandra Snyder Charen, MD	\circ	\bigcirc	\bigcirc	\circ	\circ						
Catherine J. Wu, MD	\circ	\bigcirc	\circ	\circ	\circ						
If you perceived commercial bias, please indicate the presenter and topic and/or what SITC could do to avoid such bias.											
Based upon your participation in this activity, do you intend to change your practice behavior? (Choose only one of the following options.) I do plan to implement changes in my practice based on the information presented. My current practice has been reinforced by the information presented. I need more information before I will change my practice.											
If you plan to change your practice behavior, wh	at changes do you p	olan to imp	lement? (Ch	oose all tha	it apply.)						
 Apply latest guidelines 	Choice of treat	tment/mana	gement app	roach							
Change in clinical trial design	Change in curr	ent practice	for referral								
Change in pharmaceutical therapy	Change in diffe	Change in differential diagnosis									
Change in non-pharmaceutical therapy	Other:	J									
 Change in diagnostic testing 											



How confident are you	that you will b	e able to m	iake your intei	nded chang	es?						
O Very confident	Somewhat co	onfident	O Unsure	O Not	very confident						
Thinking about how yo are likely to benefit in			tivity will influ	ence your p	oatient care, h	now many of your patients					
O Fewer than 50	(O 100-149			○ 200 or mo	re					
O 50 – 99	(O 150-199			O Not Applicable						
Which of the following	do you anticip	ate will be	the primary b	arrier to im	plementing t	hese changes?					
O Formulary restriction	s (O Patient a	dherence/comp	oliance	O Insurance,	financial issues					
○ Time constraints	(○ Lack of m	t related adverse								
System constraintssystem or other)	(healthcare	Other, pl	ease specify:								
What topics would you	like to see add	lressed at f	uture SITC Wo	rkshops?							
How would you rate th	e downloadabl	e SITC 2015	5 Meeting App	?							
○ Excellent	○ Average	\circ	Poor	\bigcirc I \bigcirc	did not know it	t was available					
Of the following, in wh	ich form would		r to receive th Electronic, Pap	•	nd evaluatior	is? (choose <u>only one</u>)					
How do you prefer to r	eceive the type	of informa	ation/educatio	n presente	d in this meet	ing?					
O Participating in a live	e webinar			\circ	Journal ar	ticles					
O Participating in a sel	f paced online c	ourse		\circ	Podcasts						
O Archived session rec	ordings of live e	events		\bigcirc	Other:						
Attending a live ever	nt										
What social media tech	nologies do yo	u use profe	essionally? (Fill	in all that a	pply.)						
○ LinkedIn	\circ	YouTube		\circ	Pinterest						
O Facebook	\circ	OncologyT	ube	0	Blogs						
O Twitter	\circ	Instagram		0	Other:						
Are you a member of S	ITC?	○ Yes	○No								

Please provion would like to	-				dress a	nd are	ea of	inter	est sł	nould	you	wish	to b	e mo	re in	volve	ed in	SITC	or
If SITC could	addres	s only	y ONE	Eissue	as a S	Society	in th	ne ne	xt 12	mon	ths, v	what	shou	ıld it	be?				
Request for (Credit (*requ	ired f	ields)															
O I do not wi of education	•	•			•	survey	for th	nis act	tivity	to hel	p de	termi	ne its	effe	ctiver	ness a	ınd gı	uide t	he typ
Name*											D	egree	, *						
Organization	າ										Sp	oecial	ty*						
Address*																			
City, State, Z	IP*																		
Telephone																			
	IMI					cate w	ill be	EMA	ILED nt leg	-		sted (email	l add	ress*	belo	w		
			*			address eive yo					-							<u> </u>	
For Physiciar O I participat O I participat	ed in the	ne ent nly pa	rt of t	he act	ivity ar	nd clair	n	_ cre											
(See program	schedu	le for	sessio	n-by-s	ession	credit	inforn	natio	n)										

Please return completed form to the SITC registration desk or evaluation return box.





